Back to Search
Start Over
First experience of using valsartan/sacubitril in women with heart failure and breast cancer receiving anthracycline-based adjuvant chemotherapy
- Source :
- Медицинский совет, Vol 0, Iss 16, Pp 42-48 (2019)
- Publication Year :
- 2019
- Publisher :
- Remedium, Ltd., 2019.
-
Abstract
- Objective. Comparison of the cardioprotective efficacy of valsartan/sacubitril and candesartan in women with heart failure (HF) and an initially reduced left ventricular ejection fraction receiving breast cancer chemotherapy.Material and methods. A prospective study included 112 women aged 53 to 65 years with systolic heart failure, who received surgical treatment for breast cancer followed by adjuvant polychemotherapy according to the FAC scheme (fluorouracil + doxorubicin + cyclophosphamide) - 6 cycles with intervals between 21 days of administration. After randomization, HF therapy with nebivolol, eplerenone, and valsartan/sacubitril (n = 55) or candesartan (n = 57) was performed. A general clinical laboratory study, electrocardiography, daily Holter monitoring of an electrocardiogram, echocardiography, a 6-minute walk test, quality of life assessment were performed initially and repeatedly after 1, 3, and 6 chemotherapy courses.Results. Both groups showed a tendency to troponin I level increase and a significant decrease in the concentration of N-terminal prohormone of brain natriuretic peptide. Only the valsartan/sacubitril group showed a statistically significant increase in the 6-minute walk distance, suppression of ventricular cardiac arrhythmias, improved indicators of systolic function of the left ventricle and quality of life when the Minnesota questionnaire was used.Conclusion. The first randomized trial of valsartan/sacubitril showed superiority compared to candesartan in the treatment of heart failure in women with breast cancer, who received adjuvant chemotherapy, which included anthracycline antibiotic, doxorubicin.
- Subjects :
- medicine.medical_specialty
valsartan/sacubitril
Anthracycline
medicine.medical_treatment
heart failure
030204 cardiovascular system & hematology
doxorubicin
Sacubitril
03 medical and health sciences
breast cancer
candesartan
0302 clinical medicine
Breast cancer chemotherapy
Internal medicine
medicine
Ejection fraction
business.industry
General Medicine
medicine.disease
Nebivolol
Candesartan
Valsartan
030220 oncology & carcinogenesis
Heart failure
Cardiology
Medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 26585790 and 2079701X
- Database :
- OpenAIRE
- Journal :
- Medical Council
- Accession number :
- edsair.doi.dedup.....c57409b758b448dab1a993d91c622ade